TransMedics Group, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During our fiscal quarter ended December 31, 2025, certain of our directors and officers entered into a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions, and written plans as “Rule 10b5-1 trading plans” and each one as a “Rule 10b5-1 trading plan.”
We describe the material terms of these Rule 10b5-1 trading plans in the table below.
Rule 10b5-1 Trading Plans
| Maximum | ||||||
|---|---|---|---|---|---|---|
| Number | ||||||
| of Securities to | ||||||
| Scheduled · be Purchased or | ||||||
| Action · Commencement · Termination · Sold Pursuant to · Covers | ||||||
| and Date | of Trading | of Trading | Security | the Rule 10b5-1 | Purchase | |
| Director/Officer | of Action | Period | Period (1) | Covered | Trading Plan (2)(3) | Or Sale |
| Tamer Khayal | Adoption12/11/2025 | 16-Mar-26 | 17-Mar-27 | Common Stock | 22,928 | Sale |
(1)
The plan is subject to earlier termination under certain circumstances specified in the plan, including upon the sale or purchase (as applicable) of all shares subject to the plan and upon either party to a plan giving notice of termination within the time prescribed under the plan.
(2)
Subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock.
(3)
The maximum number of securities to be sold pursuant to the Rule 10b5-1 Trading Plan is equal to 22,928, plus shares that may be received by Dr. Khayal in connection with vesting of restricted stock units prior to the scheduled termination date and carryover shares from a prior 10b5-1 plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.